Ardelyx Cost Of Revenue Over Time
| ARDX Stock | USD 5.07 0.27 5.06% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Ardelyx Performance and Ardelyx Correlation. Ardelyx |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ardelyx. If investors know Ardelyx will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ardelyx listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.32) | Revenue Per Share | Quarterly Revenue Growth 0.742 | Return On Assets | Return On Equity |
The market value of Ardelyx is measured differently than its book value, which is the value of Ardelyx that is recorded on the company's balance sheet. Investors also form their own opinion of Ardelyx's value that differs from its market value or its book value, called intrinsic value, which is Ardelyx's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ardelyx's market value can be influenced by many factors that don't directly affect Ardelyx's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Ardelyx's value and its price as these two are different measures arrived at by different means. Investors typically determine if Ardelyx is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ardelyx's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Cost Of Revenue Analysis
Compare Ardelyx and related stocks such as BioLineRx, Lexicon Pharmaceuticals, and Seres Therapeutics Cost Of Revenue Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BLRX | 7.2 M | 22.6 M | 21.5 M | 19 M | 0.0 | 39 K | 0.0 | 0.0 | 0.0 | 940 K | 934 K | 702 K | 654 K | 3.7 M | 3.3 M | 4.4 M |
| LXRX | (2 M) | 103.5 M | 95.4 M | 103.9 M | 101.2 M | 95.2 M | 164 M | 1.9 M | 2.5 M | 3.2 M | 1.9 M | 55 M | 427 K | 85 K | 76.5 K | 72.7 K |
| MCRB | 10.7 M | 10.7 M | 10.7 M | 10.7 M | 10.7 M | 728 K | 82 M | 89.5 M | 96 M | 80.1 M | 90.6 M | 1.7 M | 1 M | 704 K | 633.6 K | 601.9 K |
| IBRX | 323 K | 323 K | 323 K | 323 K | 323 K | 9 M | 9 M | 9 M | 9 M | 9 M | 9.1 M | 24.2 M | 24.2 M | 18.5 M | 21.3 M | 13.5 M |
| HEPA | 26.7 K | 26.7 K | 26.7 K | 26.7 K | 26.7 K | 26.7 K | 26.7 K | 26.7 K | 26.7 K | 26.7 K | 34.5 K | 86.1 K | 77.5 K | 67.1 K | 77.2 K | 64.2 K |
| VSTM | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 165 K | 2.8 M | 33.7 M | 206 K | 118 K | 62 K | 71.3 K | 67.7 K |
| MREO | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 24.6 M | 34.6 M | 22.7 M | 23.6 M | 16.3 M | 17.9 M | 936 K | 2.6 M | 2.3 M | 2.2 M |
| TERN | 65 K | 65 K | 65 K | 65 K | 65 K | 65 K | 65 K | 65 K | 65 K | 195 K | 394 K | 512 K | 1 M | 881 K | 1 M | 564.5 K |
| PDSB | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 98.4 K | 98.4 K | 176.3 K | 246.4 K | 49.1 K | 57.3 K | 65.9 K | 98.6 K |
| INZY | 83 K | 83 K | 83 K | 83 K | 83 K | 83 K | 83 K | 83 K | 83 K | 83 K | 217 K | 1.1 M | 1.2 M | 1.3 M | 1.5 M | 841.1 K |
| HOOK | 9.8 M | 9.8 M | 9.8 M | 9.8 M | 9.8 M | 9.8 M | 9.8 M | 9.8 M | 22 M | 46.3 M | 53.1 M | 4.6 M | 3.6 M | 3.6 M | 3.2 M | 3 M |
Ardelyx and related stocks such as BioLineRx, Lexicon Pharmaceuticals, and Seres Therapeutics Cost Of Revenue description
Cost of Revenue is found on Ardelyx income statement and represents the costs associated with goods and services Ardelyx provides. Indirect cost, such as salaries, is not included. In other words, cost of revenue is the total cost incurred to obtain a sale. It is more than the traditional cost of goods sold, since it includes specific selling and marketing activities.My Equities
My Current Equities and Potential Positions
Additional Tools for Ardelyx Stock Analysis
When running Ardelyx's price analysis, check to measure Ardelyx's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ardelyx is operating at the current time. Most of Ardelyx's value examination focuses on studying past and present price action to predict the probability of Ardelyx's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ardelyx's price. Additionally, you may evaluate how the addition of Ardelyx to your portfolios can decrease your overall portfolio volatility.